 |
|
|
| |
48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204
|
| |
| |
EASL 2024 June 5-8 Milan Italy>
Tarik Asselah1, Vladimir Chulanov12, Pietro Lampertico3,4, Heiner Wedemeyer5, Adrian Streinu-Cercel6,9, Victor Pantea7, Stefan Lazar8, Gheorghe Placinta7, George Sebastian Gherlan9,10, Pavel Bogomolov11, Tatyana Stepanova12, Viacheslav Morozov13, Vladimir Syutkin14, Olga Sagalova15, Vladimir Gorodin16, Dmitry Manuilov17, Renee-Claude Mercier17, Lei Ye17, Grace Chee17, Ben L. Da17, Audrey H. Lau17, Anu Osinusi17, Marc Bourliere18, Vlad Ratziu19, Stanilas Pol20, Marie-Noelle Hilleret21, Fabien Zoulim22
|
| |
|
|
|
|
|
